STING1 and neoplasm: Delivery of uniSTING-mRNA via LNPs demonstrated potent efficacy in diverse tumours, including TNBCs, LLC1, B16-F10 and advanced orthotopic/metastatic liver tumour models surpassing existing STING agonists.